CMPX (Compass Therapeutics) Float Percentage Of Total Shares Outstanding : 70.88% (As of Mar. 22, 2025)

View and export this data going back to 2020. Start your Free Trial

What is Compass Therapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Compass Therapeutics's float shares is 98.01 Mil. Compass Therapeutics's total shares outstanding is 138.28 Mil. Compass Therapeutics's float percentage of total shares outstanding is 70.88%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Compass Therapeutics's Insider Ownership is 8.81%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Compass Therapeutics's Institutional Ownership is 73.68%.

Compass Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Compass Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	98.01	/	138.28
	=	70.88%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Compass Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Compass Therapeutics Inc (NAS:CMPX) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

80 Guest Street, Suite 601, Boston, MA, USA, 02135

Website

https://www.compasstherapeutics.com

Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.

Executives

Richard S Lindahl	director	NEXTEL, 2001 EDMUND HALLEY DR, RESTON VA 20191
Thomas J. Schuetz	director, officer: Chief Executive Officer	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
David M Wurzer	director	C/O CURAGEN CORP, 555 LONG WHARF DR. 11TH FL., NEW HAVEN CT 06511
Vered Bisker-leib	officer: Chief Operating Officer	C/O COMPASS, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carl L Gordon	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
James P Boylan	director	C/O ENAVATE SCIENCES, 2884 SAND HILL RD., STE 100, MENLO PARK CA 94025
Ellen Chiniara	director	51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453
Mary Ann Gray	director	201 W 70TH ST, SUITE 23K, NEW YORK NY 10023
Philip Ferneau	director	10 ALLEN STREET, HANOVER NH 03755
Orbimed Capital Gp V Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Miranda Jayne Toledano	director	C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135
Susan Kalled	officer: Chief Scientific Officer	COMPASS THERAPEUTICS, INC., 80 GUEST ST., SUITE 601, BOSTON MA 02135
Brett Kaplan	director	C/O PREVAIL THERAPEUTICS INC., 430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016